Table 6.
Associations between mammographic density at diagnosis and pathological complete response following neoadjuvant chemotherapy - premenopausal patients
| BI-RADSa | N | N of cases | OR (95% CI) | |
|---|---|---|---|---|
| Model 1 | a | 4 | 2 | (ref) |
| b | 27 | 2 | 0.08 (0.01–0.91) | |
| c | 71 | 13 | 0.22 (0.03–1.74) | |
| d | 13 | 1 | 0.08 (0.00–1.41) | |
| Model 2 | a | 4 | 2 | (ref) |
| b | 27 | 2 | 0.05 (0.00–0.74) | |
| c | 71 | 13 | 0.15 (0.01–1.52) | |
| d | 13 | 1 | 0.05 (0.00–1.49) | |
| Model 3 | a | 4 | 2 | (ref) |
| b | 27 | 2 | 0.07 (0.00–1.38) | |
| c | 71 | 13 | 0.15 (0.01–1.67) | |
| d | 13 | 1 | 0.03 (0.00–0.76) |
Odds ratio (OR) for pathological complete response (pCR)
Model 1: crude analysis
Model 2: minimally adjusted (age, BMI, pregnancies) analysis
Model 3: fully adjusted (model 2 + ER, PR, Ki67, HER2, and tumor size at diagnosis) analysis
aThroughout the table BI-RADS breast composition is intended